Saniona AB – Product Pipeline Review

Global Markets Direct’s, ‘Saniona AB – Product Pipeline Review – 2016’, provides an overview of the Saniona AB’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Saniona AB, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Saniona AB

The report provides overview of Saniona AB including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Saniona AB’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Saniona AB’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Saniona AB’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Saniona AB

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Saniona AB’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Saniona AB Snapshot 6

Saniona AB Overview 6

Key Information 6

Key Facts 6

Saniona AB - Research and Development Overview 7

Key Therapeutic Areas 7

Saniona AB - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

Pipeline Products - Out-Licensed Products 13

Out-Licensed Products/Combination Treatment Modalities 14

Saniona AB - Pipeline Products Glance 15

Saniona AB - Clinical Stage Pipeline Products 15

Phase II Products/Combination Treatment Modalities 15

Phase I Products/Combination Treatment Modalities 16

Saniona AB - Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

Discovery Products/Combination Treatment Modalities 18

Saniona AB - Drug Profiles 19

(metoprolol + tesofensine) 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

NS-2359 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

tesofensine 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

AN-721 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

AN-788 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

AN-346 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

AN-470 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

AN-761 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

NS-9283 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecule to Agonize GABAA Alpha 2 and Alpha 3 for Neuropathic Pain 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Small Molecules to Agonize nAChR Alpha7 for Pain and Alzheimer's Disease 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Small Molecule to Activate TREK for Pain 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Small Molecule to Agonize GABA Alpha 4 Delta Receptor for Sleep Disorders, Stress and Autism 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Small Molecule to Agonize GABAA Receptor Subunit Alpha-4 and Gamma for Epilepsy 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Small Molecule to Agonize nAChR Alpha6 for Parkinson's Disease 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Small Molecule to Block TREK for Depression 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Small Molecule to Inhibit Monoamine Reuptake for Pain 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Saniona AB - Pipeline Analysis 44

Saniona AB - Pipeline Products by Target 44

Saniona AB - Pipeline Products by Route of Administration 46

Saniona AB - Pipeline Products by Molecule Type 47

Saniona AB - Pipeline Products by Mechanism of Action 48

Saniona AB - Recent Pipeline Updates 50

Saniona AB - Dormant Projects 51

Saniona AB - Discontinued Pipeline Products 52

Discontinued Pipeline Product Profiles 52

NS-2359 52

tesofensine 52

Saniona AB - Locations And Subsidiaries 53

Head Office 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Tables

List of Tables

Saniona AB, Key Information 6

Saniona AB, Key Facts 6

Saniona AB – Pipeline by Indication, 2016 9

Saniona AB – Pipeline by Stage of Development, 2016 10

Saniona AB – Monotherapy Products in Pipeline, 2016 11

Saniona AB – Combination Treatment Modalities in Pipeline, 2016 12

Saniona AB – Out-Licensed Products in Pipeline, 2016 13

Saniona AB – Out-Licensed Products/ Combination Treatment Modalities, 2016 14

Saniona AB – Phase II, 2016 15

Saniona AB – Phase I, 2016 16

Saniona AB – Preclinical, 2016 17

Saniona AB – Discovery, 2016 18

Saniona AB – Pipeline by Target, 2016 45

Saniona AB – Pipeline by Route of Administration, 2016 46

Saniona AB – Pipeline by Molecule Type, 2016 47

Saniona AB – Pipeline Products by Mechanism of Action, 2016 49

Saniona AB – Recent Pipeline Updates, 2016 50

Saniona AB – Dormant Developmental Projects,2016 51

Saniona AB – Discontinued Pipeline Products, 2016 52

List of Figures

List of Figures

Saniona AB – Pipeline by Top 10 Indication, 2016 8

Saniona AB – Pipeline by Stage of Development, 2016 10

Saniona AB – Monotherapy Products in Pipeline, 2016 11

Saniona AB – Combination Treatment Modalities in Pipeline, 2016 12

Saniona AB – Pipeline by Top 10 Target, 2016 44

Saniona AB – Pipeline by Route of Administration, 2016 46

Saniona AB – Pipeline by Molecule Type, 2016 47

Saniona AB – Pipeline Products by Top 10 Mechanism of Action, 2016 48

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports